Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview study.
Saved in:
| Title: | Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview study. |
|---|---|
| Authors: | Merikle E; Clinical Outcomes Assessment Consultant, Parksville, BC, Canada., Presnall C; Independent Researcher, Tucson, AZ, USA., Feaster T; Acumen Pharmaceuticals, Inc, Newton, MA, USA., Moxon R; Acumen Pharmaceuticals, Inc, Newton, MA, USA., Siemers E; Acumen Pharmaceuticals, Inc, Newton, MA, USA., Kerwin D; Kerwin Medical Center, Dallas, TX, USA., Cline S; Acumen Pharmaceuticals, Inc, Newton, MA, USA. scline@acumenpharm.com. |
| Source: | Trials [Trials] 2026 Mar 23; Vol. 27 (1). Date of Electronic Publication: 2026 Mar 23. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1745-6215 |
|---|---|
| DOI: | 10.1186/s13063-026-09656-w |
